about
Ceritinib in ALK-rearranged non-small-cell lung cancer.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Sorafenib: a review of its use in advanced hepatocellular carcinomaBendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsIncreased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatmentRole of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide.Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: A case report.KRAS mutation in lung metastases from colorectal cancer: prognostic implications.An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.The present and the future landscape of treatment of advanced hepatocellular carcinoma.In situ follicular lymphoma: pathologic characteristics and diagnostic features.Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.The role of inflammation in lymphoma.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography.Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Prognostic and predictive value of MET deregulation in non-small cell lung cancerBrentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Regorafenib for the treatment of unresectable hepatocellular carcinoma.Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialClinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?
P50
Q27852989-B5625F68-37A2-44FE-A937-40DE42A988A2Q27853360-F979D4E9-5873-4F03-99E0-5155C711F2F5Q28235646-21CEA2D2-A3F0-44F0-8214-35CC85FFFA73Q33415782-1CE19C81-5D96-4D80-BFA2-BAACA4EB1FA2Q33420273-B5566789-0F3C-4486-89B3-22640D33809BQ33421897-30035CAD-646F-49F5-9472-524849481E1AQ33430547-339BF742-6DD3-4B1B-B9A1-BD13F3C5B319Q33433311-29FAD758-5DF5-4D95-80BB-B1B04AE10660Q33433659-006BBAB0-61A5-4BA0-9E58-21799E189679Q33918135-6FDA5169-897E-4C1E-9A91-161506A162C0Q34196471-CAB0FE20-0748-47AA-91A9-C35E7F583860Q34663499-E219A3C7-6D95-4661-8781-6DC8A2157E4AQ34964958-68D840C5-9A16-4274-9234-9760FF2C4D18Q35149263-90631D80-C3B1-495B-A712-EBDFF10336E6Q35227986-D28D6589-432B-4A97-B9A2-9D1318DA1332Q35584266-F434297A-6BA2-41AE-BE09-62E303594296Q35676452-BC1873EF-933D-40E7-9F77-47C5FD3DF1A8Q36028504-49A56431-EB9E-46C4-B680-A4F22B32B7CCQ36502159-8D828848-3FEE-44EE-96B7-7307CE61BDAFQ36528345-B9F493B9-2C81-410E-A16A-DA2218F2FFBFQ37470361-2463433E-1950-4D06-84AC-24368848C79CQ37687269-6CAF89B3-6EB6-476F-9C78-1CDDB7C68483Q37765048-3C6821C4-BDFC-49FF-8F9F-25F917032C77Q37874211-30E88108-D6CE-465C-818A-BBB2D8CE1E1AQ38186853-12771995-881A-455C-8B02-D3BAA36D205EQ38211083-6675A5F6-AA00-431E-A636-AB404820E751Q38368587-B59F1817-A042-4362-9660-368A87767829Q38373761-1F02ACF6-BEFB-4400-8569-B145E6CE73E1Q38400475-9A50A5A6-419F-4788-9622-BD3FFB9C0E49Q38425167-A1081EC8-1AE5-4653-9F91-FB132E08A24DQ38432288-AD360830-3BE4-4052-912F-3EB5132A55A3Q38466376-1EB42A70-A047-4831-95E2-9B86C319782FQ38493294-95CD92AF-1C25-42D2-BBBF-BDDE053B3AB2Q38551290-CD48D9B7-955D-4415-95DA-1B751FCCE521Q38557033-1AE01B5A-C306-4D03-B0E4-EC8A276AE13FQ38674803-025006EE-3B08-42F0-A492-A2BA677BE869Q38906747-091AAC3A-228C-464F-90DC-80C0EB872E8EQ38909086-84848093-D1E0-4753-AA7A-26377B1C0281Q38930717-4F6DE555-84D5-4C6F-93CF-73A60F7E506CQ38938622-812DD4AB-0908-413E-9241-CDABE9C128E0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Armando Santoro
@ast
Armando Santoro
@en
Armando Santoro
@es
Armando Santoro
@nl
Armando Santoro
@sl
type
label
Armando Santoro
@ast
Armando Santoro
@en
Armando Santoro
@es
Armando Santoro
@nl
Armando Santoro
@sl
prefLabel
Armando Santoro
@ast
Armando Santoro
@en
Armando Santoro
@es
Armando Santoro
@nl
Armando Santoro
@sl
P106
P21
P31
P496
0000-0003-1709-9492